B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen.

Non-Hodgkin lymphoma associated with pregnancy is rare. Rituximab based chemotherapy is now considered the standard of care and considered safe for the treatment of diffuse large B-cell lymphoma (DLBCL) during pregnancy but little is known about its safety profile on the fetus. A 32 y primigravida was diagnosed as DLBCL at 20 wk of gestation. She received rituximab containing chemotherapy with successful pregnancy outcome. Though the baby was absolutely healthy, B-cell was totally absent in the cord blood.